Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin
Executive Summary
Law has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.
You may also be interested in...
Dalvance Protocol Accord With FDA + Actavis Marketing = Home Run?
With a Special Protocol Agreement and an experienced sales team lined up, all the firm has to do now is get hospitals excited about an expensive antibiotic in a highly-genericized market.
2020 Antibiotic Goal in Jeopardy? HHS Analysis Shows Need For Earlier, Larger Incentives
Goal of 10 new antibiotics by 2020 may be unlikely given current marketplace for antibiotics, some experts predict as a new study shows recent proposals to revive development may be focused at wrong point in development timeline. Study suggests need for large increases in government funding.
Dalvance: First QIDP Antibiotic Breaks New Regulatory Ground; Label Doesn’t
Durata has post-marketing requirements to continue resistance-related studies, but its label includes stewardship language similar to other antibiotics.